<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>IgG fractions were purified on <z:chebi fb="0" ids="2511">Sepharose</z:chebi> anti-human IgG column from eight sera of healthy donors, having no anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> (aCL) activity as measured by anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> ELISA assay (aCL-ELISA) </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the IgG fractions, after elution with 4.9 M <z:chebi fb="0" ids="6636">MgCl2</z:chebi>, reacted with CL </plain></SENT>
<SENT sid="2" pm="."><plain>The antigen-binding characteristics of the IgG fractions purified from <z:mpath ids='MPATH_458'>normal</z:mpath> human serum (NHS) were similar to those of IgG fractions purified from sera of four patients with the anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome (APLS) </plain></SENT>
<SENT sid="3" pm="."><plain>Competition assay confirmed the specificity of the binding of the purified IgG fractions to CL </plain></SENT>
<SENT sid="4" pm="."><plain>The same results have been achieved with IgG fractions purified on <z:chebi fb="0" ids="2511">Sepharose</z:chebi> Protein-A column </plain></SENT>
<SENT sid="5" pm="."><plain>The binding to CL was completely inhibited by either whole NHS and sera from various animal species, or by beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (beta 2-GPI) </plain></SENT>
<SENT sid="6" pm="."><plain>Our results support the notion of the existence of both natural anti-CL antibodies and serum inhibitor(s) in sera of healthy individuals </plain></SENT>
<SENT sid="7" pm="."><plain>It is conceivable that in part the pathogenesis of APLS entails defects in the natural inhibitors of aCL antibodies </plain></SENT>
</text></document>